Φορτώνει......
Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
The α(2)-adrenergic receptor agonist guanfacine, in its extended-release formulation (GXR), is the most recent nonstimulant medication approved in several countries for the treatment of attention-deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive pharmacotherapy to stimulants in...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Neuropsychiatr Dis Treat |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4455846/ https://ncbi.nlm.nih.gov/pubmed/26064054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S65735 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|